Global Tumor Immunity Therapy Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Tumor Immunity Therapy Industry Forecast” looks at past sales and reviews total world Tumor Immunity Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Immunity Therapy sales for 2023 through 2029. With Tumor Immunity Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunity Therapy industry.
This Insight Report provides a comprehensive analysis of the global Tumor Immunity Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immunity Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunity Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunity Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunity Therapy.
The global Tumor Immunity Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Immunity Therapy players cover Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunity Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “Tumor Immunity Therapy Industry Forecast” looks at past sales and reviews total world Tumor Immunity Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Immunity Therapy sales for 2023 through 2029. With Tumor Immunity Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunity Therapy industry.
This Insight Report provides a comprehensive analysis of the global Tumor Immunity Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immunity Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunity Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunity Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunity Therapy.
The global Tumor Immunity Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Immunity Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Immunity Therapy players cover Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunity Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Immune Checkpoint Inhibitor
- Cytokine Immunotherapy
- Cancer Vaccine
- Car-t Cell Therapy
- Others
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Roche AG
- AstraZeneca, Plc
- Sanofi S.A.
- Dendreon Pharmaceuticals
- Novartis
- Gilead Sciences Inc.
- IMVAQ Therapeutics
- Arch Oncology
- Juno Therapeutics
- Refuge
- Lepu Biopharma
- Genoimmune
- TCR Cure
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Immunity Therapy Market Size 2018-2029
2.1.2 Tumor Immunity Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Tumor Immunity Therapy Segment by Type
2.2.1 Immune Checkpoint Inhibitor
2.2.2 Cytokine Immunotherapy
2.2.3 Cancer Vaccine
2.2.4 Car-t Cell Therapy
2.2.5 Others
2.3 Tumor Immunity Therapy Market Size by Type
2.3.1 Tumor Immunity Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
2.4 Tumor Immunity Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Tumor Immunity Therapy Market Size by Application
2.5.1 Tumor Immunity Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
3 TUMOR IMMUNITY THERAPY MARKET SIZE BY PLAYER
3.1 Tumor Immunity Therapy Market Size Market Share by Players
3.1.1 Global Tumor Immunity Therapy Revenue by Players (2018-2023)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunity Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TUMOR IMMUNITY THERAPY BY REGIONS
4.1 Tumor Immunity Therapy Market Size by Regions (2018-2023)
4.2 Americas Tumor Immunity Therapy Market Size Growth (2018-2023)
4.3 APAC Tumor Immunity Therapy Market Size Growth (2018-2023)
4.4 Europe Tumor Immunity Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Tumor Immunity Therapy Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Tumor Immunity Therapy Market Size by Country (2018-2023)
5.2 Americas Tumor Immunity Therapy Market Size by Type (2018-2023)
5.3 Americas Tumor Immunity Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunity Therapy Market Size by Region (2018-2023)
6.2 APAC Tumor Immunity Therapy Market Size by Type (2018-2023)
6.3 APAC Tumor Immunity Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Tumor Immunity Therapy by Country (2018-2023)
7.2 Europe Tumor Immunity Therapy Market Size by Type (2018-2023)
7.3 Europe Tumor Immunity Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Immunity Therapy by Region (2018-2023)
8.2 Middle East & Africa Tumor Immunity Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Tumor Immunity Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TUMOR IMMUNITY THERAPY MARKET FORECAST
10.1 Global Tumor Immunity Therapy Forecast by Regions (2024-2029)
10.1.1 Global Tumor Immunity Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Tumor Immunity Therapy Forecast
10.1.3 APAC Tumor Immunity Therapy Forecast
10.1.4 Europe Tumor Immunity Therapy Forecast
10.1.5 Middle East & Africa Tumor Immunity Therapy Forecast
10.2 Americas Tumor Immunity Therapy Forecast by Country (2024-2029)
10.2.1 United States Tumor Immunity Therapy Market Forecast
10.2.2 Canada Tumor Immunity Therapy Market Forecast
10.2.3 Mexico Tumor Immunity Therapy Market Forecast
10.2.4 Brazil Tumor Immunity Therapy Market Forecast
10.3 APAC Tumor Immunity Therapy Forecast by Region (2024-2029)
10.3.1 China Tumor Immunity Therapy Market Forecast
10.3.2 Japan Tumor Immunity Therapy Market Forecast
10.3.3 Korea Tumor Immunity Therapy Market Forecast
10.3.4 Southeast Asia Tumor Immunity Therapy Market Forecast
10.3.5 India Tumor Immunity Therapy Market Forecast
10.3.6 Australia Tumor Immunity Therapy Market Forecast
10.4 Europe Tumor Immunity Therapy Forecast by Country (2024-2029)
10.4.1 Germany Tumor Immunity Therapy Market Forecast
10.4.2 France Tumor Immunity Therapy Market Forecast
10.4.3 UK Tumor Immunity Therapy Market Forecast
10.4.4 Italy Tumor Immunity Therapy Market Forecast
10.4.5 Russia Tumor Immunity Therapy Market Forecast
10.5 Middle East & Africa Tumor Immunity Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Tumor Immunity Therapy Market Forecast
10.5.2 South Africa Tumor Immunity Therapy Market Forecast
10.5.3 Israel Tumor Immunity Therapy Market Forecast
10.5.4 Turkey Tumor Immunity Therapy Market Forecast
10.5.5 GCC Countries Tumor Immunity Therapy Market Forecast
10.6 Global Tumor Immunity Therapy Forecast by Type (2024-2029)
10.7 Global Tumor Immunity Therapy Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Information
11.2.2 Merck & Co., Inc. Tumor Immunity Therapy Product Offered
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck & Co., Inc. Main Business Overview
11.2.5 Merck & Co., Inc. Latest Developments
11.3 Roche AG
11.3.1 Roche AG Company Information
11.3.2 Roche AG Tumor Immunity Therapy Product Offered
11.3.3 Roche AG Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Roche AG Main Business Overview
11.3.5 Roche AG Latest Developments
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Information
11.4.2 AstraZeneca, Plc Tumor Immunity Therapy Product Offered
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 AstraZeneca, Plc Main Business Overview
11.4.5 AstraZeneca, Plc Latest Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Information
11.5.2 Sanofi S.A. Tumor Immunity Therapy Product Offered
11.5.3 Sanofi S.A. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sanofi S.A. Main Business Overview
11.5.5 Sanofi S.A. Latest Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Information
11.6.2 Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Dendreon Pharmaceuticals Main Business Overview
11.6.5 Dendreon Pharmaceuticals Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Tumor Immunity Therapy Product Offered
11.7.3 Novartis Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Information
11.8.2 Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Gilead Sciences Inc. Main Business Overview
11.8.5 Gilead Sciences Inc. Latest Developments
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Information
11.9.2 IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 IMVAQ Therapeutics Main Business Overview
11.9.5 IMVAQ Therapeutics Latest Developments
11.10 Arch Oncology
11.10.1 Arch Oncology Company Information
11.10.2 Arch Oncology Tumor Immunity Therapy Product Offered
11.10.3 Arch Oncology Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Arch Oncology Main Business Overview
11.10.5 Arch Oncology Latest Developments
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Information
11.11.2 Juno Therapeutics Tumor Immunity Therapy Product Offered
11.11.3 Juno Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Juno Therapeutics Main Business Overview
11.11.5 Juno Therapeutics Latest Developments
11.12 Refuge
11.12.1 Refuge Company Information
11.12.2 Refuge Tumor Immunity Therapy Product Offered
11.12.3 Refuge Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Refuge Main Business Overview
11.12.5 Refuge Latest Developments
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Information
11.13.2 Lepu Biopharma Tumor Immunity Therapy Product Offered
11.13.3 Lepu Biopharma Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Lepu Biopharma Main Business Overview
11.13.5 Lepu Biopharma Latest Developments
11.14 Genoimmune
11.14.1 Genoimmune Company Information
11.14.2 Genoimmune Tumor Immunity Therapy Product Offered
11.14.3 Genoimmune Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Genoimmune Main Business Overview
11.14.5 Genoimmune Latest Developments
11.15 TCR Cure
11.15.1 TCR Cure Company Information
11.15.2 TCR Cure Tumor Immunity Therapy Product Offered
11.15.3 TCR Cure Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 TCR Cure Main Business Overview
11.15.5 TCR Cure Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Immunity Therapy Market Size 2018-2029
2.1.2 Tumor Immunity Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Tumor Immunity Therapy Segment by Type
2.2.1 Immune Checkpoint Inhibitor
2.2.2 Cytokine Immunotherapy
2.2.3 Cancer Vaccine
2.2.4 Car-t Cell Therapy
2.2.5 Others
2.3 Tumor Immunity Therapy Market Size by Type
2.3.1 Tumor Immunity Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
2.4 Tumor Immunity Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Tumor Immunity Therapy Market Size by Application
2.5.1 Tumor Immunity Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
3 TUMOR IMMUNITY THERAPY MARKET SIZE BY PLAYER
3.1 Tumor Immunity Therapy Market Size Market Share by Players
3.1.1 Global Tumor Immunity Therapy Revenue by Players (2018-2023)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunity Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TUMOR IMMUNITY THERAPY BY REGIONS
4.1 Tumor Immunity Therapy Market Size by Regions (2018-2023)
4.2 Americas Tumor Immunity Therapy Market Size Growth (2018-2023)
4.3 APAC Tumor Immunity Therapy Market Size Growth (2018-2023)
4.4 Europe Tumor Immunity Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Tumor Immunity Therapy Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Tumor Immunity Therapy Market Size by Country (2018-2023)
5.2 Americas Tumor Immunity Therapy Market Size by Type (2018-2023)
5.3 Americas Tumor Immunity Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunity Therapy Market Size by Region (2018-2023)
6.2 APAC Tumor Immunity Therapy Market Size by Type (2018-2023)
6.3 APAC Tumor Immunity Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Tumor Immunity Therapy by Country (2018-2023)
7.2 Europe Tumor Immunity Therapy Market Size by Type (2018-2023)
7.3 Europe Tumor Immunity Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Immunity Therapy by Region (2018-2023)
8.2 Middle East & Africa Tumor Immunity Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Tumor Immunity Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TUMOR IMMUNITY THERAPY MARKET FORECAST
10.1 Global Tumor Immunity Therapy Forecast by Regions (2024-2029)
10.1.1 Global Tumor Immunity Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Tumor Immunity Therapy Forecast
10.1.3 APAC Tumor Immunity Therapy Forecast
10.1.4 Europe Tumor Immunity Therapy Forecast
10.1.5 Middle East & Africa Tumor Immunity Therapy Forecast
10.2 Americas Tumor Immunity Therapy Forecast by Country (2024-2029)
10.2.1 United States Tumor Immunity Therapy Market Forecast
10.2.2 Canada Tumor Immunity Therapy Market Forecast
10.2.3 Mexico Tumor Immunity Therapy Market Forecast
10.2.4 Brazil Tumor Immunity Therapy Market Forecast
10.3 APAC Tumor Immunity Therapy Forecast by Region (2024-2029)
10.3.1 China Tumor Immunity Therapy Market Forecast
10.3.2 Japan Tumor Immunity Therapy Market Forecast
10.3.3 Korea Tumor Immunity Therapy Market Forecast
10.3.4 Southeast Asia Tumor Immunity Therapy Market Forecast
10.3.5 India Tumor Immunity Therapy Market Forecast
10.3.6 Australia Tumor Immunity Therapy Market Forecast
10.4 Europe Tumor Immunity Therapy Forecast by Country (2024-2029)
10.4.1 Germany Tumor Immunity Therapy Market Forecast
10.4.2 France Tumor Immunity Therapy Market Forecast
10.4.3 UK Tumor Immunity Therapy Market Forecast
10.4.4 Italy Tumor Immunity Therapy Market Forecast
10.4.5 Russia Tumor Immunity Therapy Market Forecast
10.5 Middle East & Africa Tumor Immunity Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Tumor Immunity Therapy Market Forecast
10.5.2 South Africa Tumor Immunity Therapy Market Forecast
10.5.3 Israel Tumor Immunity Therapy Market Forecast
10.5.4 Turkey Tumor Immunity Therapy Market Forecast
10.5.5 GCC Countries Tumor Immunity Therapy Market Forecast
10.6 Global Tumor Immunity Therapy Forecast by Type (2024-2029)
10.7 Global Tumor Immunity Therapy Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Information
11.2.2 Merck & Co., Inc. Tumor Immunity Therapy Product Offered
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck & Co., Inc. Main Business Overview
11.2.5 Merck & Co., Inc. Latest Developments
11.3 Roche AG
11.3.1 Roche AG Company Information
11.3.2 Roche AG Tumor Immunity Therapy Product Offered
11.3.3 Roche AG Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Roche AG Main Business Overview
11.3.5 Roche AG Latest Developments
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Information
11.4.2 AstraZeneca, Plc Tumor Immunity Therapy Product Offered
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 AstraZeneca, Plc Main Business Overview
11.4.5 AstraZeneca, Plc Latest Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Information
11.5.2 Sanofi S.A. Tumor Immunity Therapy Product Offered
11.5.3 Sanofi S.A. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sanofi S.A. Main Business Overview
11.5.5 Sanofi S.A. Latest Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Information
11.6.2 Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Dendreon Pharmaceuticals Main Business Overview
11.6.5 Dendreon Pharmaceuticals Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Tumor Immunity Therapy Product Offered
11.7.3 Novartis Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Information
11.8.2 Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Gilead Sciences Inc. Main Business Overview
11.8.5 Gilead Sciences Inc. Latest Developments
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Information
11.9.2 IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 IMVAQ Therapeutics Main Business Overview
11.9.5 IMVAQ Therapeutics Latest Developments
11.10 Arch Oncology
11.10.1 Arch Oncology Company Information
11.10.2 Arch Oncology Tumor Immunity Therapy Product Offered
11.10.3 Arch Oncology Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Arch Oncology Main Business Overview
11.10.5 Arch Oncology Latest Developments
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Information
11.11.2 Juno Therapeutics Tumor Immunity Therapy Product Offered
11.11.3 Juno Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Juno Therapeutics Main Business Overview
11.11.5 Juno Therapeutics Latest Developments
11.12 Refuge
11.12.1 Refuge Company Information
11.12.2 Refuge Tumor Immunity Therapy Product Offered
11.12.3 Refuge Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Refuge Main Business Overview
11.12.5 Refuge Latest Developments
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Information
11.13.2 Lepu Biopharma Tumor Immunity Therapy Product Offered
11.13.3 Lepu Biopharma Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Lepu Biopharma Main Business Overview
11.13.5 Lepu Biopharma Latest Developments
11.14 Genoimmune
11.14.1 Genoimmune Company Information
11.14.2 Genoimmune Tumor Immunity Therapy Product Offered
11.14.3 Genoimmune Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Genoimmune Main Business Overview
11.14.5 Genoimmune Latest Developments
11.15 TCR Cure
11.15.1 TCR Cure Company Information
11.15.2 TCR Cure Tumor Immunity Therapy Product Offered
11.15.3 TCR Cure Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 TCR Cure Main Business Overview
11.15.5 TCR Cure Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Tumor Immunity Therapy Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Immune Checkpoint Inhibitor
Table 3. Major Players of Cytokine Immunotherapy
Table 4. Major Players of Cancer Vaccine
Table 5. Major Players of Car-t Cell Therapy
Table 6. Major Players of Others
Table 7. Tumor Immunity Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 10. Tumor Immunity Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 13. Global Tumor Immunity Therapy Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Tumor Immunity Therapy Revenue Market Share by Player (2018-2023)
Table 15. Tumor Immunity Therapy Key Players Head office and Products Offered
Table 16. Tumor Immunity Therapy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Tumor Immunity Therapy Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Tumor Immunity Therapy Market Size Market Share by Regions (2018-2023)
Table 21. Global Tumor Immunity Therapy Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Tumor Immunity Therapy Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Tumor Immunity Therapy Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Tumor Immunity Therapy Market Size Market Share by Country (2018-2023)
Table 25. Americas Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 27. Americas Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 29. APAC Tumor Immunity Therapy Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Table 31. APAC Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 33. APAC Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 35. Europe Tumor Immunity Therapy Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Tumor Immunity Therapy Market Size Market Share by Country (2018-2023)
Table 37. Europe Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 39. Europe Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Tumor Immunity Therapy Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Tumor Immunity Therapy
Table 48. Key Market Challenges & Risks of Tumor Immunity Therapy
Table 49. Key Industry Trends of Tumor Immunity Therapy
Table 50. Global Tumor Immunity Therapy Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Tumor Immunity Therapy Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Tumor Immunity Therapy Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Tumor Immunity Therapy Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Bristol-Myers Squibb Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 55. Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
Table 56. Bristol-Myers Squibb Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Bristol-Myers Squibb Main Business
Table 58. Bristol-Myers Squibb Latest Developments
Table 59. Merck & Co., Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 60. Merck & Co., Inc. Tumor Immunity Therapy Product Offered
Table 61. Merck & Co., Inc. Main Business
Table 62. Merck & Co., Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Merck & Co., Inc. Latest Developments
Table 64. Roche AG Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 65. Roche AG Tumor Immunity Therapy Product Offered
Table 66. Roche AG Main Business
Table 67. Roche AG Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Roche AG Latest Developments
Table 69. AstraZeneca, Plc Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 70. AstraZeneca, Plc Tumor Immunity Therapy Product Offered
Table 71. AstraZeneca, Plc Main Business
Table 72. AstraZeneca, Plc Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. AstraZeneca, Plc Latest Developments
Table 74. Sanofi S.A. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 75. Sanofi S.A. Tumor Immunity Therapy Product Offered
Table 76. Sanofi S.A. Main Business
Table 77. Sanofi S.A. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Sanofi S.A. Latest Developments
Table 79. Dendreon Pharmaceuticals Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 80. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
Table 81. Dendreon Pharmaceuticals Main Business
Table 82. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Dendreon Pharmaceuticals Latest Developments
Table 84. Novartis Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 85. Novartis Tumor Immunity Therapy Product Offered
Table 86. Novartis Main Business
Table 87. Novartis Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Novartis Latest Developments
Table 89. Gilead Sciences Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 90. Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
Table 91. Gilead Sciences Inc. Main Business
Table 92. Gilead Sciences Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Gilead Sciences Inc. Latest Developments
Table 94. IMVAQ Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 95. IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
Table 96. IMVAQ Therapeutics Main Business
Table 97. IMVAQ Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. IMVAQ Therapeutics Latest Developments
Table 99. Arch Oncology Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 100. Arch Oncology Tumor Immunity Therapy Product Offered
Table 101. Arch Oncology Main Business
Table 102. Arch Oncology Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Arch Oncology Latest Developments
Table 104. Juno Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 105. Juno Therapeutics Tumor Immunity Therapy Product Offered
Table 106. Juno Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Juno Therapeutics Main Business
Table 108. Juno Therapeutics Latest Developments
Table 109. Refuge Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 110. Refuge Tumor Immunity Therapy Product Offered
Table 111. Refuge Main Business
Table 112. Refuge Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 113. Refuge Latest Developments
Table 114. Lepu Biopharma Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 115. Lepu Biopharma Tumor Immunity Therapy Product Offered
Table 116. Lepu Biopharma Main Business
Table 117. Lepu Biopharma Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 118. Lepu Biopharma Latest Developments
Table 119. Genoimmune Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 120. Genoimmune Tumor Immunity Therapy Product Offered
Table 121. Genoimmune Main Business
Table 122. Genoimmune Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 123. Genoimmune Latest Developments
Table 124. TCR Cure Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 125. TCR Cure Tumor Immunity Therapy Product Offered
Table 126. TCR Cure Main Business
Table 127. TCR Cure Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 128. TCR Cure Latest Developments
Table 1. Tumor Immunity Therapy Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Immune Checkpoint Inhibitor
Table 3. Major Players of Cytokine Immunotherapy
Table 4. Major Players of Cancer Vaccine
Table 5. Major Players of Car-t Cell Therapy
Table 6. Major Players of Others
Table 7. Tumor Immunity Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 10. Tumor Immunity Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 13. Global Tumor Immunity Therapy Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Tumor Immunity Therapy Revenue Market Share by Player (2018-2023)
Table 15. Tumor Immunity Therapy Key Players Head office and Products Offered
Table 16. Tumor Immunity Therapy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Tumor Immunity Therapy Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Tumor Immunity Therapy Market Size Market Share by Regions (2018-2023)
Table 21. Global Tumor Immunity Therapy Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Tumor Immunity Therapy Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Tumor Immunity Therapy Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Tumor Immunity Therapy Market Size Market Share by Country (2018-2023)
Table 25. Americas Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 27. Americas Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 29. APAC Tumor Immunity Therapy Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Table 31. APAC Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 33. APAC Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 35. Europe Tumor Immunity Therapy Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Tumor Immunity Therapy Market Size Market Share by Country (2018-2023)
Table 37. Europe Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 39. Europe Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Tumor Immunity Therapy Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Tumor Immunity Therapy Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Tumor Immunity Therapy Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Tumor Immunity Therapy
Table 48. Key Market Challenges & Risks of Tumor Immunity Therapy
Table 49. Key Industry Trends of Tumor Immunity Therapy
Table 50. Global Tumor Immunity Therapy Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Tumor Immunity Therapy Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Tumor Immunity Therapy Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Tumor Immunity Therapy Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Bristol-Myers Squibb Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 55. Bristol-Myers Squibb Tumor Immunity Therapy Product Offered
Table 56. Bristol-Myers Squibb Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Bristol-Myers Squibb Main Business
Table 58. Bristol-Myers Squibb Latest Developments
Table 59. Merck & Co., Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 60. Merck & Co., Inc. Tumor Immunity Therapy Product Offered
Table 61. Merck & Co., Inc. Main Business
Table 62. Merck & Co., Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Merck & Co., Inc. Latest Developments
Table 64. Roche AG Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 65. Roche AG Tumor Immunity Therapy Product Offered
Table 66. Roche AG Main Business
Table 67. Roche AG Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Roche AG Latest Developments
Table 69. AstraZeneca, Plc Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 70. AstraZeneca, Plc Tumor Immunity Therapy Product Offered
Table 71. AstraZeneca, Plc Main Business
Table 72. AstraZeneca, Plc Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. AstraZeneca, Plc Latest Developments
Table 74. Sanofi S.A. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 75. Sanofi S.A. Tumor Immunity Therapy Product Offered
Table 76. Sanofi S.A. Main Business
Table 77. Sanofi S.A. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Sanofi S.A. Latest Developments
Table 79. Dendreon Pharmaceuticals Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 80. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offered
Table 81. Dendreon Pharmaceuticals Main Business
Table 82. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Dendreon Pharmaceuticals Latest Developments
Table 84. Novartis Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 85. Novartis Tumor Immunity Therapy Product Offered
Table 86. Novartis Main Business
Table 87. Novartis Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Novartis Latest Developments
Table 89. Gilead Sciences Inc. Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 90. Gilead Sciences Inc. Tumor Immunity Therapy Product Offered
Table 91. Gilead Sciences Inc. Main Business
Table 92. Gilead Sciences Inc. Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Gilead Sciences Inc. Latest Developments
Table 94. IMVAQ Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 95. IMVAQ Therapeutics Tumor Immunity Therapy Product Offered
Table 96. IMVAQ Therapeutics Main Business
Table 97. IMVAQ Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. IMVAQ Therapeutics Latest Developments
Table 99. Arch Oncology Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 100. Arch Oncology Tumor Immunity Therapy Product Offered
Table 101. Arch Oncology Main Business
Table 102. Arch Oncology Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Arch Oncology Latest Developments
Table 104. Juno Therapeutics Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 105. Juno Therapeutics Tumor Immunity Therapy Product Offered
Table 106. Juno Therapeutics Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Juno Therapeutics Main Business
Table 108. Juno Therapeutics Latest Developments
Table 109. Refuge Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 110. Refuge Tumor Immunity Therapy Product Offered
Table 111. Refuge Main Business
Table 112. Refuge Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 113. Refuge Latest Developments
Table 114. Lepu Biopharma Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 115. Lepu Biopharma Tumor Immunity Therapy Product Offered
Table 116. Lepu Biopharma Main Business
Table 117. Lepu Biopharma Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 118. Lepu Biopharma Latest Developments
Table 119. Genoimmune Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 120. Genoimmune Tumor Immunity Therapy Product Offered
Table 121. Genoimmune Main Business
Table 122. Genoimmune Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 123. Genoimmune Latest Developments
Table 124. TCR Cure Details, Company Type, Tumor Immunity Therapy Area Served and Its Competitors
Table 125. TCR Cure Tumor Immunity Therapy Product Offered
Table 126. TCR Cure Main Business
Table 127. TCR Cure Tumor Immunity Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 128. TCR Cure Latest Developments
LIST OF FIGURES
Figure 1. Tumor Immunity Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Immunity Therapy Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Tumor Immunity Therapy Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Tumor Immunity Therapy Sales Market Share by Country/Region (2022)
Figure 8. Tumor Immunity Therapy Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Tumor Immunity Therapy Market Size Market Share by Type in 2022
Figure 10. Tumor Immunity Therapy in Hospital
Figure 11. Global Tumor Immunity Therapy Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Tumor Immunity Therapy in Clinic
Figure 13. Global Tumor Immunity Therapy Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Global Tumor Immunity Therapy Market Size Market Share by Application in 2022
Figure 15. Global Tumor Immunity Therapy Revenue Market Share by Player in 2022
Figure 16. Global Tumor Immunity Therapy Market Size Market Share by Regions (2018-2023)
Figure 17. Americas Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 18. APAC Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 19. Europe Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 20. Middle East & Africa Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 21. Americas Tumor Immunity Therapy Value Market Share by Country in 2022
Figure 22. United States Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 23. Canada Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 24. Mexico Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 25. Brazil Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 26. APAC Tumor Immunity Therapy Market Size Market Share by Region in 2022
Figure 27. APAC Tumor Immunity Therapy Market Size Market Share by Type in 2022
Figure 28. APAC Tumor Immunity Therapy Market Size Market Share by Application in 2022
Figure 29. China Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 30. Japan Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 31. Korea Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 32. Southeast Asia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 33. India Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 34. Australia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 35. Europe Tumor Immunity Therapy Market Size Market Share by Country in 2022
Figure 36. Europe Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Figure 37. Europe Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Figure 38. Germany Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 39. France Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 40. UK Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 41. Italy Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 42. Russia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Figure 44. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Figure 45. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Figure 46. Egypt Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 47. South Africa Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 48. Israel Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 49. Turkey Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 50. GCC Country Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 51. Americas Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 52. APAC Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 53. Europe Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 54. Middle East & Africa Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 55. United States Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 56. Canada Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 57. Mexico Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 58. Brazil Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 59. China Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 60. Japan Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 61. Korea Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 62. Southeast Asia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 63. India Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 64. Australia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 65. Germany Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 66. France Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 67. UK Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 68. Italy Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 69. Russia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 70. Spain Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 71. Egypt Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 72. South Africa Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 73. Israel Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 74. Turkey Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 75. GCC Countries Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 76. Global Tumor Immunity Therapy Market Size Market Share Forecast by Type (2024-2029)
Figure 77. Global Tumor Immunity Therapy Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Tumor Immunity Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Immunity Therapy Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Tumor Immunity Therapy Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Tumor Immunity Therapy Sales Market Share by Country/Region (2022)
Figure 8. Tumor Immunity Therapy Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Tumor Immunity Therapy Market Size Market Share by Type in 2022
Figure 10. Tumor Immunity Therapy in Hospital
Figure 11. Global Tumor Immunity Therapy Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Tumor Immunity Therapy in Clinic
Figure 13. Global Tumor Immunity Therapy Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Global Tumor Immunity Therapy Market Size Market Share by Application in 2022
Figure 15. Global Tumor Immunity Therapy Revenue Market Share by Player in 2022
Figure 16. Global Tumor Immunity Therapy Market Size Market Share by Regions (2018-2023)
Figure 17. Americas Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 18. APAC Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 19. Europe Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 20. Middle East & Africa Tumor Immunity Therapy Market Size 2018-2023 ($ Millions)
Figure 21. Americas Tumor Immunity Therapy Value Market Share by Country in 2022
Figure 22. United States Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 23. Canada Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 24. Mexico Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 25. Brazil Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 26. APAC Tumor Immunity Therapy Market Size Market Share by Region in 2022
Figure 27. APAC Tumor Immunity Therapy Market Size Market Share by Type in 2022
Figure 28. APAC Tumor Immunity Therapy Market Size Market Share by Application in 2022
Figure 29. China Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 30. Japan Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 31. Korea Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 32. Southeast Asia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 33. India Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 34. Australia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 35. Europe Tumor Immunity Therapy Market Size Market Share by Country in 2022
Figure 36. Europe Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Figure 37. Europe Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Figure 38. Germany Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 39. France Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 40. UK Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 41. Italy Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 42. Russia Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 43. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Region (2018-2023)
Figure 44. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Type (2018-2023)
Figure 45. Middle East & Africa Tumor Immunity Therapy Market Size Market Share by Application (2018-2023)
Figure 46. Egypt Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 47. South Africa Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 48. Israel Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 49. Turkey Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 50. GCC Country Tumor Immunity Therapy Market Size Growth 2018-2023 ($ Millions)
Figure 51. Americas Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 52. APAC Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 53. Europe Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 54. Middle East & Africa Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 55. United States Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 56. Canada Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 57. Mexico Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 58. Brazil Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 59. China Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 60. Japan Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 61. Korea Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 62. Southeast Asia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 63. India Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 64. Australia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 65. Germany Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 66. France Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 67. UK Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 68. Italy Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 69. Russia Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 70. Spain Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 71. Egypt Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 72. South Africa Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 73. Israel Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 74. Turkey Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 75. GCC Countries Tumor Immunity Therapy Market Size 2024-2029 ($ Millions)
Figure 76. Global Tumor Immunity Therapy Market Size Market Share Forecast by Type (2024-2029)
Figure 77. Global Tumor Immunity Therapy Market Size Market Share Forecast by Application (2024-2029)
